Healthcare Industry News: ultrasound imaging
News Release - May 10, 2006
GE Healthcare Introduces the World's First and Only Compact Ultrasound System with 4D Imaging CapabilitiesFDA Clears GE'S Voluson i
New Laptop-Size 4D Ultrasound System Brings Breakthrough OB/GYN Technology to the Point of Care
WASHINGTON--(HSMN NewsFeed)--May 10, 2006--GE Healthcare, a unit of General Electric Company (NYSE:GE ), today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the Voluson i, the world's first and only 4D compact ultrasound system designed specifically for women's healthcare, including obstetric, gynecological, and other clinical applications. This new compact system allows clinicians to make real-time diagnoses, particularly for high-risk patients, by providing high-quality 4D imaging to wherever the patient is located. The Voluson i is being showcased May 8-10 in GE Healthcare's booth, #1405, Hall A at the 54th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Washington, DC.
Voluson i will help enhance the efficiency and reach of clinicians by offering the functionality and high performance of a console-size ultrasound system in a portable design that weighs slightly more than the average newborn. This benefit, coupled with the system's ease-of-use, enables facilities of all sizes to offer 4D imaging as the standard of care for prenatal women. The portability of the Voluson i also makes it ideal for community and rural clinics, as well as mobile imaging services. "GE's Voluson i is a technology breakthrough for women's healthcare that can expand the reach of the proven clinical benefits of 4D and volume imaging," said Omar Ishrak, president and CEO of GE Healthcare's Clinical Systems business. "The Voluson i will support a completely new level of efficiency for OB/GYN physicians, enabling them to deliver patient care anywhere it's needed."
"With its ease of use and amazing diagnostic image quality, this portable ultrasound system makes it easy for me to go to the patient to perform an ultrasound scan, rather than the reverse. The remarkable portability this system offers will impact the care I give my patients," said Dr. John Hobbins, MD, Chief of Obstetrics and Director of the Prenatal Diagnosis and Genetics Center at the University of Colorado Health Science Center.
According to Ishrak, there is a need for more specialized, high-quality point of care systems to meet the growing demands for diagnosis on the spot. "Voluson i addresses one of the biggest challenges OB/GYN physicians face in caring for their high-risk patients - access to complete, real-time information that allows them to make clinical decisions at the patient's bedside with confidence," said Ishrak.
The Voluson i is FDA cleared and is now commercially available in the United States.
ABOUT GE HEALTHCARE
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $15 billion unit of General Electric Company (NYSE:GE ). Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Source: GE Healthcare
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.